Ophthalmic surgery, lasers & imaging retina · 2025
Intravitreal Methotrexate for the Treatment and Prevention of Proliferative Vitreoretinopathy in Pediatric Patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bouaziz Michael, Jiao George, Zhu Daniel, Lee Jessica G, Rhee David, Romero Juan M, Ferrone Philip J
Аннотация
BACKGROUND AND OBJECTIVE: The aim of this study was to report on the use of intravitreal methotrexate for proliferative vitreoretinopathy (PVR) in pediatric patients.
PATIENTS AND METHODS: This is a retrospective chart review of pediatric patients treated with intravitreal methotrexate for PVR. Primary outcome measures included final visual acuity at last follow-up visit, and incidence of recurrent detachments following initiation of therapy.
RESULTS: Patients received an average of ten injections of intravitreal methotrexate. The average follow-up period was 10 months. Seven out of nine (78%) patients did not detach again following initiation of methotrexate therapy. All patients (100%) were attached at last follow-up visit. There were no keratitis or corneal epithelial defects during follow-up. Visual acuity improved from a median of hand motions to counting fingers at last follow-up visit.
CONCLUSIONS: Data from this small and variable sample size demonstrates the potential of intravitreal methotrexate injections to be an effective agent for the treatment and prevention of PVR in the pediatric population.
PATIENTS AND METHODS: This is a retrospective chart review of pediatric patients treated with intravitreal methotrexate for PVR. Primary outcome measures included final visual acuity at last follow-up visit, and incidence of recurrent detachments following initiation of therapy.
RESULTS: Patients received an average of ten injections of intravitreal methotrexate. The average follow-up period was 10 months. Seven out of nine (78%) patients did not detach again following initiation of methotrexate therapy. All patients (100%) were attached at last follow-up visit. There were no keratitis or corneal epithelial defects during follow-up. Visual acuity improved from a median of hand motions to counting fingers at last follow-up visit.
CONCLUSIONS: Data from this small and variable sample size demonstrates the potential of intravitreal methotrexate injections to be an effective agent for the treatment and prevention of PVR in the pediatric population.